BrightPath Biotherapeutics
GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC
Phase 2
Terminated
- Conditions
- Metastatic NSCLC
- Interventions
- Biological: GRN-1201 + Pembrolizumab
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- BrightPath Biotherapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT03417882
- Locations
- 🇺🇸
Florida Hosptial Cancer Center- AdventHealth, Orlando, Florida, United States
🇺🇸Orchard Healthcare, Skokie, Illinois, United States
🇺🇸Virginia Cancer Institute, Richmond, Virginia, United States
Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma
Phase 1
Completed
- Conditions
- Melanoma
- Interventions
- Biological: GRN-1201
- First Posted Date
- 2016-03-02
- Last Posted Date
- 2018-06-14
- Lead Sponsor
- BrightPath Biotherapeutics
- Target Recruit Count
- 18
- Registration Number
- NCT02696356
- Locations
- 🇺🇸
University of Pittsburg, Pittsburgh, Pennsylvania, United States
🇺🇸Providence Health and Services, Providence Portland Medical Center, Portland, Oregon, United States
🇺🇸Huntsman Cancer Institute, Salt Lake City, Utah, United States
© Copyright 2025. All Rights Reserved by MedPath